Distobram - General Information
An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10% component of the antibiotic complex, nebramycin, produced by the same species. [PubChem]
Pharmacology of Distobram
Distobram, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections.
Distobram for patients
TOBI is in a class of antibiotics that have caused hearing loss, dizziness, kidney damage, and harm to a fetus.
Ringing in the ears and hoarseness were two symptoms that were seen in more patients taking TOBI than placebo
in research studies. Patients with cystic fibrosis can have many symptoms. Some of these symptoms may be related
to your medications. If you have new or worsening symptoms, you should tell your doctor.
Hearing: You should tell your doctor if you have ringing in the ears, dizziness, or any changes in hearing.
Kidney Damage: Inform your doctor if you have any history of kidney problems.
Pregnancy: If you want to become pregnant or are pregnant while on TOBI, you should talk with your doctor about
the possibility of TOBI causing any harm.
Nursing Mothers: If you are nursing a baby, you should talk with your doctor before using TOBI.
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME®, Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
Concurrent and/or sequential use of TOBI with other drugs with neurotoxic or ototoxic potential should be avoided. Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
TOBI is contraindicated in patients with a known hypersensitivity to any aminoglycoside.
Additional information about Distobram
Distobram Indication: For the treatment of pseudomonas aeruginosa lung infections
Mechanism Of Action: Distobram binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Distobram may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Tobramycin
Synonyms: 3'-Deoxykanamycin B; Tobramycin Sulfate
Drug Category: Anti-Bacterial Agents; Aminoglycosides
Drug Type: Small Molecule; Approved; Investigational
Absorption: Not Available
Toxicity (Overdose): LD50=441mg/kg (s.c. in mice)
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Distobram: Liquid Intravenous
Powder, for solution Intravenous
Solution Respiratory (inhalation)
Chemical IUPAC Name: 4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
Chemical Formula: C18H37N5O9
Tobramycin on Wikipedia: https://en.wikipedia.org/wiki/Tobramycin
Organisms Affected: Enteric bacteria and other eubacteria